Please assess the completion status of the following clinical trial:

Trial Title: ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage four (IV) NSCLC.~2. Must have documented ALK rearrangement.~3. Have sufficient tumor tissue available for central analysis.~4. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.~5. Recovered from toxicities related to prior anticancer therapy to National Cancer Institute (of the United States) (NCI) Common Terminology Criteria for Adverse Events (version 4.0) (CTCAE v 4.0) grade be less than or equal to (\<=) 1.~6. Are a male or female participants greater than or equal to (\>=)18 years old.~7. Have adequate organ function, as defined by the study protocol.~8. Have Eastern Cooperative Oncology Group (ECOG) performance status \<=2.~9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of \<= 450 millisecond (msec) in males or \<=470 msec in females.~10. For female participants of childbearing potential, have a negative pregnancy test documented prior to randomization.~11. For female and male participants who are fertile, agree to use a highly effective form of contraception, as defined by the study protocol.~12. Provide signed and dated informed consent indicating that the participants has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.~13. Have the willingness and ability to comply with scheduled visit and study procedures.~Exclusion Criteria:~1. Previously received an investigational antineoplastic agent for NSCLC.~2. Previously received any prior tyrosine kinase inhibitor (TKI), including ALK-targeted TKIs.~3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.~4. Received chemotherapy or radiation within 14 days of first dose of study drug, except stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).~5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of study drug.~6. Had major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.~7. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.~8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization.~9. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.~10. Be pregnant, planning a pregnancy, or breastfeeding.~11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.~12. Have uncontrolled hypertension.~13. Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.~14. Have an ongoing or active infection.~15. Have a known history of human immunodeficiency virus (HIV) infection.~16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.~17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.~18. Have any condition or illness that, in the opinion of the investigator, would compromise participant's safety or interfere with the evaluation of the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomized Phase: Brigatinib 90 mg QD/180 QD (Type: EXPERIMENTAL): Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
- Randomized Phase: Crizotinib 250 mg BID (Type: ACTIVE_COMPARATOR): Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
- Crossover Phase: Brigatinib 90 mg QD/180 mg QD (Type: EXPERIMENTAL): Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).